Quick Answer
Monopar Therapeutics reported Operating Income of -$16.70 million for fiscal year 2025.
Monopar Therapeutics Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$16.70M | -3.4% |
| 2024 | -$16.16M | -83.0% |
| 2023 | -$8.83M | +16.2% |
| 2022 | -$10.54M | -15.4% |
| 2021 | -$9.13M | -40.2% |
| 2020 | -$6.51M | -50.5% |
| 2019 | -$4.32M | -29.8% |
| 2018 | -$3.33M | +79.9% |
| 2017 | -$16.60M | -1291.9% |
| 2016 | -$1.19M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.09M | -159.9% | -26.6% |
| June 30, 2025 | -$3.23M | -80.8% | -0.4% |
| March 31, 2025 | -$3.22M | -86.9% | -104.6% |
| September 30, 2024 | -$1.57M | +23.8% | +12.0% |
| June 30, 2024 | -$1.79M | +23.2% | -3.8% |
| March 31, 2024 | -$1.72M | +31.7% | +16.6% |
| September 30, 2023 | -$2.07M | +14.2% | +11.3% |
| June 30, 2023 | -$2.33M | +15.7% | +7.8% |
- Monopar Therapeutics showed a decrease of -3.4% in Operating Income compared to the prior fiscal year.
- Over the 2016–2025 period, Monopar Therapeutics’s operating income has declined by 1300.4% (from -$1.19 million to -$16.70 million).
- The most recent figure is from Monopar Therapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: